Novavax EMA Director Emer Cooke Says Received An Application For Novavax Monovalent Vaccine Targeting XBB 1.5 Sub Variant
Portfolio Pulse from Benzinga Newsdesk
Novavax has submitted an application for its monovalent vaccine targeting the XBB 1.5 sub variant to the European Medicines Agency (EMA), according to EMA Director Emer Cooke. The announcement was made during an ECDC press conference.
September 21, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax has applied for EMA approval for its vaccine targeting the XBB 1.5 sub variant. This could potentially open up a new market for the company if approved.
Novavax's application to the EMA for its vaccine targeting the XBB 1.5 sub variant could potentially open up a new market for the company if approved. This could have a positive impact on the company's stock in the short term as it indicates potential growth and expansion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100